351 related articles for article (PubMed ID: 19569255)
1. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
2. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
3. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
Hartmann U; Balabanov S; Ziegler P; Fellenberg J; van der Kuip H; Duyster J; Lipp HP; Bokemeyer C; Kanz L; Brümmendorf TH
Exp Hematol; 2005 May; 33(5):542-9. PubMed ID: 15850831
[TBL] [Abstract][Full Text] [Related]
4. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U; Balabanov S; Bali D; Dierlamm J; Braig M; Hartmann U; Sirma H; Günes C; Wege H; Fehse B; Gontarewicz A; Dikomey E; Borgmann K; Brümmendorf TH
Exp Hematol; 2011 Jan; 39(1):66-76.e1-2. PubMed ID: 20940029
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in patients with chronic myeloid leukemia and lymphoma.
Bitisik O; Yavuz S; Yasasever V; Dalay N
Res Commun Mol Pathol Pharmacol; 2000; 107(1-2):3-12. PubMed ID: 11334367
[TBL] [Abstract][Full Text] [Related]
6. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Campbell LJ; Fidler C; Eagleton H; Peniket A; Kusec R; Gal S; Littlewood TJ; Wainscoat JS; Boultwood J
Leukemia; 2006 Apr; 20(4):671-9. PubMed ID: 16498395
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
8. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Verstovsek S; Kantarjian H; Manshouri T; Cortes J; Faderl S; Giles FJ; Keating M; Albitar M
Cancer; 2003 Mar; 97(5):1248-52. PubMed ID: 12599232
[TBL] [Abstract][Full Text] [Related]
9. Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.
Drummond MW; Balabanov S; Holyoake TL; Brummendorf TH
Stem Cells; 2007 Aug; 25(8):1853-61. PubMed ID: 17510216
[TBL] [Abstract][Full Text] [Related]
10. The role of telomeres and telomerase complex in haematological neoplasia: the length of telomeres as a marker of carcinogenesis and prognosis of disease.
Gancarcíková M; Zemanová Z; Brezinová J; Berková A; Vcelíková S; Smigová J; Michalová K
Prague Med Rep; 2010; 111(2):91-105. PubMed ID: 20653999
[TBL] [Abstract][Full Text] [Related]
11. A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias.
Tatematsu K; Nakayama J; Danbara M; Shionoya S; Sato H; Omine M; Ishikawa F
Oncogene; 1996 Nov; 13(10):2265-74. PubMed ID: 8950994
[TBL] [Abstract][Full Text] [Related]
12. Telomerase: obviously activated in the accelerated phase of chronic myeloid leukemia.
Li G; Song YH; Qian LS; Ma XT; Wu KF
Haematologica; 2000 Nov; 85(11):1222-4. PubMed ID: 11064478
[No Abstract] [Full Text] [Related]
13. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.
Bechter OE; Eisterer W; Pall G; Hilbe W; Kühr T; Thaler J
Cancer Res; 1998 Nov; 58(21):4918-22. PubMed ID: 9810000
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
15. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies.
Hills M; Lansdorp PM
Ann N Y Acad Sci; 2009 Sep; 1176():178-90. PubMed ID: 19796246
[TBL] [Abstract][Full Text] [Related]
16. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Brummendorf TH; Ersoz I; Hartmann U; Balabanov S; Wolke H; Paschka P; Lahaye T; Berner B; Bartolovic K; Kreil S; Berger U; Gschaidmeier H; Bokemeyer C; Hehlmann R; Dietz K; Lansdorp PM; Kanz L; Hochhaus A
Ann N Y Acad Sci; 2003 May; 996():26-38. PubMed ID: 12799279
[TBL] [Abstract][Full Text] [Related]
17. [Telomeres and telomerase in leukemias].
Werda L; Skotnicki AB
Przegl Lek; 1999; 56(10):668-70. PubMed ID: 10695383
[TBL] [Abstract][Full Text] [Related]
18. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.
Pabst T; Stillner E; Neuberg D; Nimer S; Willman CL; List AF; Melo JV; Tenen DG; Mueller BU
Br J Haematol; 2006 May; 133(4):400-2. PubMed ID: 16643447
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Melo JV; Barnes DJ
Nat Rev Cancer; 2007 Jun; 7(6):441-53. PubMed ID: 17522713
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated expression of the major telomerase components in leukaemic stem cells.
Drummond MW; Hoare SF; Monaghan A; Graham SM; Alcorn MJ; Keith WN; Holyoake TL
Leukemia; 2005 Mar; 19(3):381-9. PubMed ID: 15674365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
